NO20052922D0 - Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller - Google Patents

Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller

Info

Publication number
NO20052922D0
NO20052922D0 NO20052922A NO20052922A NO20052922D0 NO 20052922 D0 NO20052922 D0 NO 20052922D0 NO 20052922 A NO20052922 A NO 20052922A NO 20052922 A NO20052922 A NO 20052922A NO 20052922 D0 NO20052922 D0 NO 20052922D0
Authority
NO
Norway
Prior art keywords
cancer cells
compositions
methods
inducing apoptosis
apoptosis
Prior art date
Application number
NO20052922A
Other languages
English (en)
Other versions
NO20052922L (no
Inventor
Quinn L Deveraux
Deborah A Knee
Pedro Aza-Blanc
Garret M Hampton
Marc Nasoff
Klaus Wagner
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of NO20052922D0 publication Critical patent/NO20052922D0/no
Publication of NO20052922L publication Critical patent/NO20052922L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20052922A 2002-11-27 2005-06-15 Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller NO20052922L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42984202P 2002-11-27 2002-11-27
US44896003P 2003-02-21 2003-02-21
US49471403P 2003-08-12 2003-08-12
US50490103P 2003-09-22 2003-09-22
PCT/US2003/037940 WO2004050895A2 (en) 2002-11-27 2003-11-25 Methods and compositions for inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
NO20052922D0 true NO20052922D0 (no) 2005-06-15
NO20052922L NO20052922L (no) 2005-08-17

Family

ID=32475709

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052922A NO20052922L (no) 2002-11-27 2005-06-15 Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller

Country Status (17)

Country Link
US (2) US7229617B2 (no)
EP (1) EP1576179B1 (no)
JP (1) JP2006514096A (no)
KR (3) KR20070122578A (no)
AT (1) ATE481092T1 (no)
AU (1) AU2003297579A1 (no)
BR (1) BR0316737A (no)
CA (1) CA2507077A1 (no)
CO (1) CO5640147A2 (no)
DE (1) DE60334247D1 (no)
EC (1) ECSP055818A (no)
MX (1) MXPA05005726A (no)
NO (1) NO20052922L (no)
PL (1) PL210174B1 (no)
PT (1) PT1576179E (no)
RU (1) RU2379056C2 (no)
WO (1) WO2004050895A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7229617B2 (en) * 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
AU2005304638A1 (en) * 2004-11-12 2006-05-18 Massachusetts Institute Of Technology Methods and compositions for treating cellular proliferative diseases
JP2008536820A (ja) * 2005-03-24 2008-09-11 アイアールエム・リミテッド・ライアビリティ・カンパニー 癌のｄｒ５アゴニストに対するｍｙｃ依存性感受性の増強
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
RU2418807C2 (ru) * 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
AU2006338198B2 (en) * 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
SG171682A1 (en) * 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
AR066913A1 (es) * 2007-06-08 2009-09-23 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
RU2010101416A (ru) * 2007-06-19 2011-07-27 Такеда Фармасьютикал Компани Лимитед (Jp) Профилактическое/лекарственное средство от рака
US20100272706A1 (en) 2007-06-22 2010-10-28 Jason Mercer Antivirals
RU2472530C2 (ru) 2007-09-24 2013-01-20 Бар-Илан Юниверсити Полимерные наночастицы, покрытые оксидом магнитного металла, и их применение
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009261919A1 (en) * 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
EP2966084B1 (en) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
US20110287001A1 (en) * 2008-09-22 2011-11-24 Tetralogic Pharmaceuticals Method of treatment
CA2745775A1 (en) * 2008-12-18 2010-07-15 Centre National De La Recherche Scientifique - Cnrs- Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof
US9527915B2 (en) 2009-11-05 2016-12-27 The Uab Research Foundation Treating basal-like genotype cancers
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
ES2625608T3 (es) * 2010-04-21 2017-07-20 Ventirx Pharmaceuticals, Inc. Aumento de la citotoxicidad celular dependiente de anticuerpos
JP5918143B2 (ja) 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
US20130266590A1 (en) 2010-12-13 2013-10-10 Novartis Ag Dimeric iap inhibitors
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20140187604A1 (en) * 2011-05-03 2014-07-03 Dana-Farber Cancer Institute, Inc. Therapeutic and diagnostic target gene in acute myeloid leukemia
RU2488408C1 (ru) * 2012-03-22 2013-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Средство и способ индукции апоптоза опухолевых клеток
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
TWI688572B (zh) 2015-01-26 2020-03-21 美商宏觀基因股份有限公司 包含dr5-結合結構域的多價分子
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
WO1995030642A1 (en) 1994-05-06 1995-11-16 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AUPQ599500A0 (en) 2000-03-02 2000-03-23 Walter And Eliza Hall Institute Of Medical Research, The Novel peptides, modulatory agents therefor and methods of using them
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
AU2001286730A1 (en) 2000-08-24 2002-03-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
JP4663232B2 (ja) * 2001-11-01 2011-04-06 ザ ユーエービー リサーチ ファウンデーション 腫瘍壊死因子関連アポトーシス誘導リガンドレセプターに対して選択的な抗体と他の治療剤の組み合わせ
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
MXPA06014795A (es) 2004-06-21 2007-03-26 Univ Washington Anticuerpos contra el virus del nilo occidental y usos terapeuticos y profilacticos de los mismos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .

Also Published As

Publication number Publication date
RU2379056C2 (ru) 2010-01-20
US7229617B2 (en) 2007-06-12
EP1576179A4 (en) 2007-06-06
CA2507077A1 (en) 2004-06-17
KR20070122578A (ko) 2007-12-31
US20070128204A1 (en) 2007-06-07
RU2005120167A (ru) 2006-03-10
KR20090046973A (ko) 2009-05-11
PL377726A1 (pl) 2006-02-06
PT1576179E (pt) 2010-12-21
US20050079172A1 (en) 2005-04-14
JP2006514096A (ja) 2006-04-27
PL210174B1 (pl) 2011-12-30
BR0316737A (pt) 2005-12-13
DE60334247D1 (de) 2010-10-28
EP1576179B1 (en) 2010-09-15
CO5640147A2 (es) 2006-05-31
EP1576179A2 (en) 2005-09-21
KR20050094811A (ko) 2005-09-28
MXPA05005726A (es) 2005-08-16
AU2003297579A1 (en) 2004-06-23
KR100915257B1 (ko) 2009-09-03
WO2004050895A2 (en) 2004-06-17
US8173128B2 (en) 2012-05-08
ATE481092T1 (de) 2010-10-15
ECSP055818A (es) 2006-01-27
NO20052922L (no) 2005-08-17
WO2004050895A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
NO20052922D0 (no) Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
TW200501960A (en) Synergistic kits and compositions for treating cancer
TW200510413A (en) Novel pyrrolodihydroisoquinolines
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200738263A (en) ANG2 and VEGF inhibitor combinations
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
ECSP067046A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparación y su uso
TW200612918A (en) Lonidamine analogs
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY160041A (en) Compositions and methods for treating parasitic infections
NO20085074L (no) Toverdige SMAC-mimetika og anvendelsene derav
HN2005029978A (es) Formulaciones
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
MX2008001538A (es) Aril piridinas y metodos para su uso.
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application